Lifevantage (LFVN) Stock Price, News & Analysis

Company Overview

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market. The company’s research and development efforts focus on leveraging cellular biology insights to create products that support antioxidant activity and overall well-being. Its sales force operates on a multi-level marketing framework, earning commissions through personal and team retail sales.

LifeVantage maintains a global presence, with active markets in North America, Europe, Asia-Pacific and South Africa. Through this international footprint, the company serves health-conscious consumers across more than 30 markets. Distributors utilize online platforms and in-person presentations to educate customers about the science behind each product and to build a recurring revenue base.

Governed by a board of directors and a senior management team, LifeVantage places emphasis on product innovation, regulatory compliance and distributor training. The company continues to explore partnerships and clinical collaborations aimed at validating its formulations and expanding its reach within the competitive health and wellness industry.

Key Stats

• Today's Range: $6.75 to $9.40
• 50-Day Range: $4.02 to $10.70
• 52-Week Range: $3.90 to $15.00
• Volume: 706,900 shs
• Average Volume: 299,772 shs
• Market Capitalization: $119.03 million
• P/E Ratio: 21.01
• Dividend Yield: 2.12%
• Price Target: $5.00
• Consensus Rating: Hold

Lifevantage Stock Analysis - MarketRank™

Lifevantage scored higher than 61% of companies evaluated by MarketBeat, and ranked 339th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Lifevantage has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.

Downside Risk

Lifevantage has a consensus price target of $5.00, representing about 46.9% downside from its current price of $9.41.

Amount of Analyst Coverage

Lifevantage has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.33%

Earnings Growth

Earnings for Lifevantage are expected to grow by 8.33% in the coming year, from $0.60 to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lifevantage is 20.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.76.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lifevantage is 20.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.50.

Price to Book Value per Share Ratio

Lifevantage has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

35.99% of the float of Lifevantage has been sold short.

Short Interest Ratio / Days to Cover

Lifevantage has a short interest ratio ("days to cover") of 9.71.

Change versus previous month

Short interest in Lifevantage has recently decreased by 1.30%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Lifevantage pays a meaningful dividend of 1.87%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Lifevantage has only been increasing its dividend for 3 years.

Dividend Coverage

The dividend payout ratio of Lifevantage is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Lifevantage will have a dividend payout ratio of 30.77% next year. This indicates that Lifevantage will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.65

News Sentiment

Lifevantage has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lifevantage this week, compared to 2 articles on an average week.

Search Interest

Only 6 people have searched for LFVN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Lifevantage to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $5,518.00 in company stock, which represents 0.0046% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Lifevantage insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,518.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

21.95% of the stock of Lifevantage is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.32% of the stock of Lifevantage is held by institutions.

Company Calendar

• Record date for 3/16 Dividend: 3/02/2026
• Ex-Dividend for 3/16 Dividend: 3/02/2026
• Dividend Payable: 3/16/2026
• Last Earnings: 5/06/2026
• Record date for 6/15 Dividend: 6/01/2026
• Ex-Dividend for 6/15 Dividend: 6/01/2026
• Today: 6/10/2026
• Dividend Payable: 6/15/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LFVN
• CIK: 849146
• Web: www.lifevantage.com
• Phone: (801) 432-9000
• Fax: 801-880-0699
• Employees: 260
• Year Founded: 1988

Price Target and Rating

• Average Price Target for Lifevantage: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: -45.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.45
• Trailing P/E Ratio: 20.40
• Forward P/E Ratio: 15.33
• P/E Growth: N/A
• Net Income: $9.81 million
• Net Margins: 2.94%
• Pretax Margin: 3.46%
• Return on Equity: 23.89%
• Return on Assets: 12.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.96
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: $195.32 million
• Price / Sales: 0.59
• Cash Flow: $0.95 per share
• Price / Cash Flow: 9.73
• Book Value: $2.75 per share
• Price / Book: 3.34

Miscellaneous

• Outstanding Shares: 12,616,000
• Free Float: 9,847,000
• Market Cap: $116.03 million
• Optionable: Optionable
• Beta: 0.69